Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217887 | 0.81 | EDNRA (0.72) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL6151676 | 0.80 | EDNRA (0.62) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL7212749 | 0.78 | EDNRA (0.64) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL27508434 | 0.78 | EDNRA (0.64) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL6151488 | 0.77 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL6151680 | 0.77 | EDNRA (0.58) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL7217783 | 0.77 | EDNRA (0.65) | EDNRAMAPTTP53KMT2A | |
| SCHEMBL7212753 | 0.76 | EDNRA (0.57) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL7211689 | 0.76 | EDNRA (0.64) | EDNRACDK2MAPTTP53TSHR | |
| SCHEMBL7211761 | 0.74 | EDNRA (0.58) | EDNRACDK2MAPTTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | claimed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6458805-B2 | ANTAGONISTS; ESPECIALLY SODIUM SALTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-10-01 | — | — | US | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | disclosed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | disclosed |
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2001-11-08 | — | — | US | disclosed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6248767-B1 | VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORP. | 2001-06-19 | — | — | US | disclosed |
| EP-1048657-A1 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | EDNRA 1/4885CDK2 3514/4885MAPT 4280/4885 |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | EDNRA 1/4885CDK2 1579/4885MAPT 1823/4885 |
| US-20010039289-A1 | Formulation of sulfonamides for treatment of endothelin-mediated disorders | EDNRA, EDNRB, ECE1 | EDNRA 1/4885CDK2 3514/4885MAPT 4104/4885 |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | EDNRA 2/4885CDK2 3578/4885MAPT 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.